drugset / Trial / NCT01429181

Efficacy & Safety Study of Nonracemic Methadone for the Relief of Chronic Peripheral Neuropathic Pain

NCT01429181

Phase 2 Completed 37 enrolled MetaPharm, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

There is a growing evidence that the d-isomer of methadone is effective in treating neuropathic pain while the l-isomer of methadone is the only effective isomer of methadone for treating somatic pain. This study will examine a combination of different amounts of the d- and l-isomers of methadone specifically tailored to the chronic peripheral neuropathic pain. Non-racemic mixture of methadone isomers will be tested in this pilot efficacy and safety study. This study will evaluate effect of the three doses of the non-racemic mixture of methadone hydrochloride patients with chronic peripheral neuropathic pain compared with a placebo. The study will also examine the minimally effective and maximally tolerated doses of the non-racemic mixture of methadone. Finally, the safety and tolerability of the non-racemic methadone therapy will be evaluated.

Timeline

Start
2012-01
Primary completion
2014-09
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Methadone Other / unclassified 15 mg
Subject Methadone Other / unclassified 30 mg
Subject Methadone Other / unclassified 40 mg